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The relationship of vitaminDwith extraskeletal complications, such as cardiovascular disease, cancer, and autoimmune disease, is of
major interest considering its roles in key biological processes and the worldwide high prevalence of vitaminD deficiency. However,
the causal relationships between vitamin D and most extraskeletal complications are weak. Currently, a heated debate over vitamin
D is being conducted according to two hypotheses. In this review, we first present the different arguments that suggest a major role
of vitamin D in a very broad type of extraskeletal complications (hypothesis #1). We then present results from recent meta-analyses
of randomized controlled trials indicating a lack of association of vitamin D with major extraskeletal complications (hypothesis
#2). We discuss different issues (e.g., causality, confounding, reverse causation, misclassification, and Mendelian randomization)
that contribute to the favoring of one hypothesis over the other. While ultimately only one hypothesis is correct, we anticipate that
the results from the ongoing randomized controlled trials will be unlikely to reconcile the divided experts.
1. Introduction
In humans, most circulating vitamin D is synthesized from
cholesterol following exposure to ultraviolet B (UVB) in
sunlight, whereas a smaller amount is derived from diet and
dietary supplements. Diet contributes only between 10% and
20% to 25(OH)D levels but becomes more important when
sunshine exposure is low [1]. Fish is the major dietary source
of vitamin D in humans.
A summary of the synthesis and metabolism of vita-
min D, which have been described in detail in multiple
reviews and textbooks [1–6], is presented below. Calcitriol,
or 1,25-dihydroxyvitaminD [1,25(OH)2D], is the hormonally
active form of vitamin D that is derived from the follow-
ing three sources: sunlight, diet, and dietary supplements
(Figure 1).
There are two precursors to active vitamin D hormones,
vitamins D
3
(cholecalciferol) and D
2
(ergocalciferol). Vita-
minD
3
is synthesized in the skin after exposure to UVB light.
SolarUVB radiation (wavelength of 290 to 315 nm) penetrates
the skin and converts 7-dehydrocholesterol to previtamin
D
3
by photolysis, which is rapidly converted to vitamin D
3
[4]. Vitamin D
3
may also be obtained from some dietary
sources and dietary supplements. VitaminD
2
(ergocalciferol)
is derived solely from the diet (and not from UVB). Both
vitamin D
3
and D
2
enter the blood circulation and are
attracted to the vitamin D binding protein (VDBP).
Vitamin D in the circulation is transported to the liver,
which is where it is converted by vitamin D-25-hydroxylase
to 25-hydroxyvitamin D [25(OH)D]. This first hydroxyla-
tion is catalyzed by the CYP27A1 enzyme. This form of
vitamin D is thought to be biologically inactive and must
be converted in the kidneys by 25(OH)D 1𝛼-hydroxylase
to its biologically active form, 1,25(OH)2D [2]. This second
hydroxylation is catalyzed by CYP27B1, which is located in
the inner mitochondrial membrane of the proximal tubule
cells of the kidneys. The 24-hydroxylation of both 25(OH)D
and 1,25(OH)D to form 24,25(OH)D and 1,24,25(OH)D
is the primary mechanism and the first step towards the
inactivation of vitamin D metabolites.
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Figure 1: Sources of vitamin D and the first steps of vitamin D synthesis.
Genomic and Nongenomic Vitamin D Functions. The actions
of vitamin D are largely mediated by genomic functions.
Vitamin D interacts with nuclear vitamin D receptor (VDR).
VDR is a ligand-induced nuclear receptor that regulates the
expression of over 900 genes throughout the genome [7, 8].
It influences the transcription of genes that are responsive to
the VDR-vitamin D complex. 1,25(OH)2D dissociates from
serum VDBP and enters the cell. Inside the cell, it binds
to and activates VDR, and the VDR-vitamin D complex
translocates from the cytosol to the nucleus, where it is
joined by the retinoid X receptor (RXR) partner [6]. The
1,25(OH)2D-VDR-RXR complex binds to specific sequences
in the promoter regions of target genes that are called vitamin
D response elements (VDREs), leading to the promotion and
modulation of the expression of the targeted genes. 25(OH)D
is less active than 1,25(OH)D2 because of its lower affinity for
VDR.
Vitamin D has also some nongenomic rapid-response
functions. In terms of its nongenomic functions, it functions
as a steroid hormone by activating signal transduction path-
ways linked to vitamin D receptors on cell membranes.
2. Hypothesis #1: Vitamin D Is Causally
Associated with Extraskeletal Complications
2.1. Vitamin D Deficiency and Associated Seasonal and
Geographic Patterns
2.1.1. High Prevalence of VitaminDDeficiency. Theworldwide
high prevalence of vitamin D deficiency is often presented
as being clearly linked with the high burden of extraskeletal
complications. In Europe, the mean serum 25(OH)D levels
(conversion factor for 25(OH)D: 1 ng/mL = 2.496 nmol/L)
reported in population-based studies have varied from
18 ng/mL (29 nmol/L) in Italy to 30 ng/mL (75 nmol/L) in
Norway but are generally very low [9]. A recent review
of vitamin D deficiency in central Europe has concluded
that 25(OH)D levels are on average below 30 ng/mL [10].
Worldwide, it is estimated that one billion people have
vitamin D deficiency [11], and it affects more than 40% of
US and Europeanmen and women [12].This high prevalence
has also been reported in a Swiss study that has calculated a
population-based estimation of vitamin D deficiency accord-
ing to 25(OH)D serum levels, reporting that 39.5% of the
population has 25(OH)D levels of <20 ng/mL (<50 nmol/L)
(vitamin D deficiency) [13].
Of course, the prevalence of vitamin D deficiency and
insufficiency depends on the definition used. Several def-
initions of vitamin D deficiency exist, some of which are
presented in Table 1. The reasons for the differences in
these definitions are partially due to the outcomes, for
which the defined cutoff levels were different (e.g., bone
fracture, parathyroid hormone (PTH) level, cardiovascular
(CV) events, and cancer). Obviously, it is very unlikely that
the risks of these outcomes all increase at the same 25(OH)D
level. Given the wide variation in the definitions of vitamin D
deficiency, Pilz et al. have suggested that the ideal 25(OH)D
concentration for overall health-related outcomes ranges
from 40 nmol/L to 120 nmol/L [14]. In fact, a more accurate
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Table 1: Examples of different vitamin D status definitions.
Mayo clinic Institute of Medicine (IOM) Pilz et al. Kidney Disease ImprovingGlobal Outcomes (KDIGO)
PMID∗: 20675513 PMID∗: 21118827 PMID∗: 21682758 PMID∗: 19644521
Severe deficiency <25 At risk of deficiency <30 Deficiency <50 Deficiency <37
Moderate deficiency 25–59.9 At risk of inadequate level 30–49 Insufficiency 50–74.9 Insufficiency 37–75
Optimal 60–200 Sufficient 50–125 Optimal 75–100 Adequate >75
Possible toxicity >200 Possible toxicity >125 Sufficiency 75–250
Intoxication >375–500
25(OH)D expressed in nmol/L. Conversion factor for 25(OH)D: 1 ng/mL = 2.496 nmol/L; ∗PMID: PubMed unique identification number.
range seems to be between 40 and 80 nmol/L according to
a recent study that has suggested the presence of a J-curve
between vitamin D level and overall mortality [15]. Debates
on the ideal vitamin D concentration have increased after
the publishing of the 2011 Institute of Medicine (IOM) report
[16]. The IOM suggested that a lower 25(OH)D level should
be used to define vitamin D deficiency and that a 25(OH)D
serum level of 20 ng/mL (50 nmol/L) is desirable for bone and
overall health [16]. While vitamin D deficiency defined as a
serum 25(OH)D level of <20 ng/mL (50 nmol/L) and vitamin
D insufficiency defined as a 25(OH)D level of between 20
and 29 ng/mL (50–75 nmol/L) have been extensively used in
epidemiological studies, the definition of vitamin D insuf-
ficiency is more controversial. Of note, a 25(OH)D level of
at least 20 ng/mL (50 nmol/L) was chosen by the IOM, with
recommended dietary allowances of 600 IU/day of vitamin
D for individuals aged 1–70 years and 800 IU/day for those
aged 71 years and older to meet the requirements of at least
97.5% of the population. Yet other definitions of vitamin
D deficiency and insufficiency are proposed in the Kidney
Disease Improving Global Outcomes (KDIGO) guidelines
[17]; serum levels of vitamin D are considered as adequate
when the concentration of 25(OH)D is higher than 30 ng/mL,
levels between 15–30 ng/mL are considered as insufficient,
and values that are lower than 15 ng/mL define the diagnosis
of vitamin D deficiency (Table 1).
Several factors have been proposed to explain the high
prevalence of vitamin D deficiency, one of which is inad-
equate vitamin D intake [18]. Using data from a 10-year
trend study (1999–2009, 𝑁 = 9,320) performed in Geneva,
Switzerland, deAbreu et al. have found that slightlymore than
10% of participants complied with dietary recommendations
for vitamin D intake [19]. This finding was in line with data
suggesting that vitamin D is one of the critical vitamins and
that its intake is below the recommended level [18, 20]. This
chronic insufficient intake of micronutrients in a population
without the emergence of immediate clinical signs is typical
of “Hidden Hunger” [20, 21].
2.1.2. Latitude and Season. Vitamin D is often presented
as the link explaining most of the observed correlations
between latitude and season with extraskeletal complica-
tions. Most vitamin D is produced in the skin from 7-
dehydrocholesterol by sunlight UVB exposure, which varies
with latitude and season [3]. UVB exposure decreases from
the equator towards the polar regions [22]. At approximately
0∘ latitude (i.e., the equator, e.g., the Republic of Seychelles),
a high level of vitamin D-effective UV radiation is present,
which varies only slightly throughout the year. On the other
hand, at approximately 40∘ latitude (e.g., Switzerland, with a
latitude of 47∘), the level of vitamin D-effective UV radiation
varies greatly throughout the year and decreases substantially
during the winter [23].
Ecological studies have reported an inverse correlation of
ischemic heart disease with sunlight and a seasonal pattern
of coronary heart disease mortality [24]. We contributed
to the largest (𝑁 = 230,000 from 15 countries) and most
comprehensive (bodymass index, waist circumference, blood
pressure, total high- (HDL) and low-density lipoprotein
(LDL) cholesterol, triglycerides, and glucose levels) study
ever conducted to assess the seasonality of cardiovascular risk
factors [25]. The results have strongly suggested that cardio-
vascular risk factors present a seasonal pattern, with lower
levels occurring during the summer and higher levels during
thewinter, suggesting that at least part of the patterningmight
be due to changes in air/outdoor temperature, air pollution,
and exposure to sunlight and thus differences in vitamin D
levels [25].
Geographic and seasonal patterns of cancer incidence and
mortality have also been reported in ecological studies [26,
27], suggesting a correlation between sunlight exposure (and,
thus, vitamin D) and cancer.
2.2. VDR Receptor, VDR Gene, and Extrarenal 1-Alpha-
Hydroxylase. The wide distribution of VDRs in humans, the
influence of vitamin D on more than 3% of the human
genome, and the extrarenal presence of 1-alpha-hydroxylase
are often presented as factors explaining the very broad
influence of vitamin D on health and disease [20].
Several biological systems have VDRs and are responsive
to vitamin D. Because one of the major biological functions
of this vitamin is to maintain calcium homeostasis, typical
responses occur in the intestines and kidneys, which is
where 1,25(OH)2D-VDR regulates genes, leading to increased
calcium and phosphate absorption. Another typical action
of vitamin D is the suppression of PTH synthesis by
1,25(OH)2D-VDR in the parathyroid glands. However, a
recent study has reported that the 1,25(OH)2D-VDR complex
controls the expression of genes and syntheses of mRNAs
that are unrelated to calcium homeostasis. In fact, one of the
reasons for the recent growing interest in the role of vitamin
D in extraskeletal complications is emerging evidence that
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VDRs are largely distributed throughout human tissues. The
list of tissues in which VDRs are distributed includes the
hepatogastrointestinal system (e.g., the colon), the respira-
tory system (e.g., the lungs), the central nervous system (e.g.,
neurons), the cardiovascular system (e.g., cardiomyocytes),
and the kidneys [28]. Thus, tissue and cellular VDR dis-
tribution is wide. Most human tissues and cell types are
responsive to 1,25(OH)2D [29, 30]. For example, the vitamin
D-VDR complex controls the expression of genes involved in
the inhibition of the renin-angiotensin system (RAS), which
influences blood pressure, as well as genes that promote the
secretion of insulin and cell proliferation and differentiation
[31–34].
VDR abundance and activity seem to play important roles
in individual responses to 1,25(OH)2D. Some VDR abun-
dance and activity are determined by VDR polymorphisms
(i.e., genetic variations that occur at a frequency of >1%
[35]) [5]. The VDR gene lies on chromosome 12 [36]. The
coding sequence of the VDR protein is comprised of eight
exons, and several (>60) genetic polymorphisms have been
identified [5, 37]. These polymorphisms may alter transcrip-
tional activity and thus VDR abundance and may modulate
cellular responsiveness to 1,25(OH)2D. In particular, there is
a polymorphic site at the 5󸀠 end of the VDR gene Fok I C/T.
This polymorphism, in contrast with the otherVDR variants,
results in an altered amino acid sequence [5, 37]. The Fok I
C allele generates a shorter VDR protein than the T allele,
and this shorter protein is thought to be more active than the
longer one [5]. Another important polymorphism is theCdx2
VDR polymorphism, which is located in the promoter region
of the VDR gene in exon 1. The Cdx2 VDR polymorphism
has been associated with VDR transcriptional activity in the
intestinal tract. The T allele has shown up to 70% greater
transcriptional activity compared with the C allele [38].
It was first estimated that the number of primary
1,25(OH)2D target genes is in the order of 100–500 per tissue,
but there seems to be manymore genomic VDR binding sites
per cell type (between 1000 and 10,000) [29]. However, as
stressed by Carlberg, some of these sitesmay not have specific
functions and may only represent noise [29].
The observations that extrarenal 1,25(OH)2D can also
be produced (extrarenal 1-alpha-hydroxylase) and that
1,25(OH)2D can act locally in the tissues where it is produced
(autocrine/paracrine activities) also support the potential
role of vitamin D in extraskeletal complications [39].
2.3. Evidence from Molecular and Animal Studies. Molecular
and animal studies have established associations of vitamin
D with extraskeletal complications. Given the abundance of
available literature on this topic, we will briefly present some
major mechanisms involved in specific but frequent chronic
extraskeletal complications, namely, CV disease (CVD) (high
blood pressure, coronary heart disease, and stroke), type II
diabetes, cancer, and chronic kidney disease (CKD).
2.3.1. Cardiovascular Disease: High Blood Pressure and
Coronary Heart Disease. Molecular evidence has revealed
effects of 1,25(OH)2D on blood pressure-related mechanisms
[34]. These mechanisms include the direct inhibition by
1,25(OH)2D of the RAS. VDR is expressed in the juxta-
glomerular apparatus and modulates renin synthesis. Mice
lacking VDRs are hyperreninemic and present with high
blood pressure and cardiac hypertrophy [40]. By contrast,
the overexpression of VDR in the mouse juxtaglomerular
apparatus leads to hyporeninemia [41]. In addition, vitamin
D can regulate blood pressure through the prevention of
secondary hyperparathyroidism [42], and it seems to have a
direct effect on vascular cells and endothelial function [43].
Different mechanisms have been proposed to explain
the association of vitamin D with coronary heart disease
[44], some of which are indirect. Vitamin D could be
related to coronary heart disease by affecting blood pressure,
glycemic control, or PTH. Other proposed mechanisms are
more directly related to atherosclerosis, cardiac tissues, and
vasculature. Animal studies have highlighted the roles of
vitaminD in cardiomyocyte remodeling in response to injury
and atherosclerosis as well as in cardiac relaxation and
contractility [45]. Serum levels of vitamin D seem to be
inversely associatedwith the extent of vascular calcification in
individuals at risk of ischemic heart disease [44, 46]. Vitamin
D could confer protection against atherosclerosis and vascu-
lar calcification by directly affecting vascular smooth muscle
cells (VSMCs).This vitamin causes an acute influx of calcium
in VSMCs that might inhibit their proliferation [47]. Vitamin
D could also be associated with coronary heart disease by
downregulating proinflammatory cytokines (e.g., TNF-𝛼 and
IL-6) and upregulating the anti-inflammatory cytokine IL-10
[44].
2.3.2. Type II Diabetes and Cancer. There is great interest in
the roles of vitaminD in the susceptibilities of type II diabetes
and metabolic syndrome [47]. The effects of vitamin D on
type II diabetes could be mediated by its role in pancreatic
𝛽-cell function, insulin resistance, or inflammation [33, 48–
50].With respect to cancer, studies using animal models have
shown that knocking outVDR inducesmany types of cancers,
including mammary, prostate, and colon cancers [26, 51].
Recently, a low vitamin D level has even been proposed as
a modulator of the link between diabetes and cancer [52].
2.3.3. Chronic Kidney Disease. CKD is defined as the persis-
tence for 3 or more months of structural and/or functional
abnormalities of the kidney [53]. CKD is associated with an
increased risk of ischemic heart disease, stroke, peripheral
vascular disease, anemia, bone disease, end-stage renal dis-
ease, and mortality. Mechanisms (beyond those related to
parathormone or calcium) by which vitamin D might be
associated with CKD are summarized in Figure 2. Vitamin
D insufficiency correlates with mortality risk among patients
with CKD and evidence has been reviewed elsewhere [54,
55]. For example, a recent meta-analysis of 20 observational
studies showed vitamin D treatment to be associated with
decreased risk of all-cause and cardiovascular mortality in
patients with CKD not requiring dialysis and patients with
end stage renal disease (ESRD) requiring dialysis [55]. This
meta-analysis also highlighted the need of well-designed
randomized controlled trials to formally assess the survival
benefits of vitamin D.
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1,25(OH)2D levels
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Figure 2:Main hypothetical mechanisms of action of vitaminD in chronic kidney disease.Mechanisms related to parathormone and calcium
are not displayed. VSMC = vascular smooth muscle cells; RAAS = renin-angiotensin-aldosterone system; NF-𝜅B = nuclear factor-𝜅B; TNF-𝛼
= tumor necrosis factor-𝛼; IL-6 = interleukin-6.
One of the mechanisms associating vitamin D with CKD
involves the nuclear factor-𝜅B (NF-𝜅B) pathway. NF-𝜅B is
a family of transcription factors that functions as a master
regulator of the immune response [56]. It regulates a wide
range of genes involved in inflammation, proliferation, and
fibrogenesis and is known to have a key role in kidney disease
[57]. A direct inhibition by 1,25(OH)2D of the (NF-𝜅B)
pathway has been reported. Both RAS and NF-𝜅B promote
the production of profibrotic and proinflammatory factors,
increase oxidative stress, and damage podocytes.
2.4. Evidence from Observational Studies. Guessous et al.
have previously reviewed evidence of the roles of vitamin
D in hypertension, coronary heart disease, and stroke [34].
Out of four observational prospective studies identified, two
have reported an inverse association between 25(OH)D level
and hypertension risk, one found no such association, and
one found an association neither with hypertension nor with
changes in blood pressure. Lower vitamin D levels have been
found to be associated with an increased risk of myocardial
infarction in a prospective study of men aged 40–75 years
[58]. Higher levels of 1,25(OH)D have been associated with
decreased risk of stroke among participants in a cohort study
conducted in Finland [59].
2.5. Economic Impact of Correcting Vitamin D Deficiency.
Finally, a potentially huge economic benefit resulting from
the correction (at the population level) of vitamin D defi-
ciency is often presented. Assuming that vitaminDdeficiency
is causally associated with extraskeletal complications, it has
been suggested that a rise in the serum 25(OH)D levels of
all Europeans to 40 nmol/L (achieved by a daily intake of
2000–3000 IU of vitamin D) would lower health-care costs
by up to 17%, which represents a reduction of 187,000 million
Euros/year [20, 60]. Thus, a single, simple intervention could
have amajor impact on the economy of health care. However,
this belief is conditional on a causal relationship of vitamin
D with extraskeletal complications that is far from being
accepted as described below.
3. Hypothesis #2: Vitamin D Is Not Causally
Associated with Extraskeletal Complications
The belief that vitamin D is not causally associated with
extraskeletal complications is mainly based on the absence
of robust evidence of this association from randomized
controlled trials (RCTs), on the potentially unfavorable effects
of vitamin D supplementation and on the precedents of other
vitamin and antioxidant trials.
3.1. Randomized Controlled Trials. To date, most associations
of vitamin D with extraskeletal complications reported by
nonexperimental studies have not been replicated in RCTs.
For example, results from observational cross-sectional and
prospective studies on the inverse association of vitamin
D intake or 25(OH)D level with blood pressure have not
been confirmed in RCTs [34]. Only one out of three RCTs
identified have found a decrease in blood pressure in the
intervention arm, but daily supplementation included both
vitamin D
3
and calcium (not vitamin D only) [61]. Two
RCTs primarily designed to determine the effect of vitamin
D supplementation on the risk of fracture have reported
conflicting effects of this vitamin on coronary heart disease
[62, 63], and no RCT has evaluated the effect of vitamin
D supplementation on coronary heart disease as a primary
outcome. Trivedi et al. have found no effect of vitamin D
supplementation on stroke [62].
To evaluate the presence of biases in the associations of
vitamin D with diverse skeletal and extraskeletal outcomes,
Theodoratou et al. have performed a review of evidence
obtained from systematic reviews and observational meta-
analyses and RCTs (i.e., an umbrella review) [64]. More than
260 systematic reviews or meta-analyses that have included
over 130 outcomes have been examined. This group has
reported a lack of highly convincing evidence of a clear link of
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vitaminDwith any outcome. Even for skeletal complications,
the authors have concluded that RCTs that examined vitamin
D only (without calcium supplementation) have failed to
demonstrate protective effects of vitamin D supplementation
on fractures or falls. Moreover, a 2014 trial sequential meta-
analysis (i.e., analysis that modeled the changing precision in
estimates of effects as trials are reported and the likely effects
of future trial results on the existing body of data) has shown
that the effects of vitaminD supplementation on extraskeletal
complications are below the futility boundary of 15% [65, 66].
Thus, future trials are unlikely to alter the conclusion of no
causal association.
A 2009 narrative review has estimated that raising
the minimum year-round serum 25(OH)D level to 100–
150 nmol/L (40 to 60 ng/mL) would prevent approximately
58,000 new cases of breast cancer and 49,000 new cases
of colorectal cancer each year in the US and Canada [67].
However, the most recent (2011) meta-analysis has concluded
that because of the potential confounding data inherent in
observational studies and the limited data obtained from
RCTs, evidence is currently insufficient to draw conclusions
about the efficacy of vitamin D supplementation for cancer
prevention [68]. A 2014 review of vitamin D status and
CVD by the UK Nutrition Society has concluded that data
supporting a causal link between vitamin D status and CVD
are mixed and ambiguous [69]. Similar conclusions were
independently published in 2011 by the North American DRI
committee [16], by the Endocrine Task Force [70], and more
recently, by others [65, 71–74]. In terms of endocrine health
and disease, available evidence does not show that vitamin
D supplementation consistently decreases the risk of type II
diabetes, Addison’s disease, or autoimmune thyroid disease
[75].
In a 2014 meta-analysis of observational studies (𝑁 = 73)
and RCTs (𝑁 = 22) of vitamin D and mortality caused
by extraskeletal complications, Chowdhury et al. have found
evidence that 25(OH)D level is inversely associated with risk
of death due to extraskeletal complications, but no evidence
of such a relationship has been found in RCTs [76]. Stratified
analysis has suggested that supplementation with vitamin D
3
and not D
2
reduces all-cause mortality [76], but most of the
trials included in the stratified analysis reported a high score
for the risk of bias.
Overall, the conclusions of the meta-analyses and reports
are in contrast with other recent reviews, which have
concluded that adequate vitamin D supplementation is an
important prophylactic factor for immunity, autoimmunity,
CVD, cancer, fertility, pregnancy, dementia, and mortality
[77]. Therefore, most scientists have acknowledged that the
prevalence of vitamin D deficiency is high (although as
discussed above, the definition of vitamin D normality is not
universal); however, based on the lack of robust evidence,
some have questioned whether it is a health problem [78].
3.2. Unfavorable Effects of Vitamin D. Vitamin D may have
unfavorable effects. For example, it could potentially con-
tribute to arterial stiffening and hypertension. Richart et al.
[79] have proposedmechanisms of the renal versus extrarenal
activation of vitamin D in relation to atherosclerosis, arterial
stiffening, and hypertension. Macrophages in atherosclerotic
lesions can locally activate 25(OH)D to form calcitriol,
which could act as a vasoactive and prooxidative substance
in VSMCs. Another concern is related to severe cases of
hypercalcemia observed in childrenwithCYP24A1mutations
[80]. Concerns extend beyond extraskeletal complications
because recent evidence has also suggested that high doses of
vitaminDmay increase the risks of fractures and falls [81, 82].
3.3. Vitamins, Antioxidants, and Hormone Replacement Ther-
apy Precedents. Skepticism about the curative and/or predic-
tive potentials of vitamin D for extraskeletal complications
has also beenmagnified by previous vitamin-related research,
in which evidence reported in observational studies has
not been replicated in RCTs [83]. RCTs of beta-carotene,
vitamin A, and vitamin E have not replicated findings
from observational studies [84]. Even worse, RCTs have
reported that some antioxidants and vitamins with supposed
favorable effects (based on observational studies) in fact have
unfavorable effects (based on RCTs). In 2008, the SELECT
trial of vitamin E and selenium in cancer prevention was
stopped prematurely because the intervention arm was more
(although not statistically significantly) likely to develop
prostate cancer [85]. This, of course, echoes the experience
and lessons learned from the Women’s Health Initiative
(WHI) study on hormone replacement therapy (HRT) [86].
This trial was stopped prematurely when an increase in
invasive breast cancer achieved statistical significance. This
trial also found increases in heart attacks and strokes in the
intervention group. These findings contrasted dramatically
with conclusions of previous epidemiologic studies, which
indicated a lack of a convincing link between breast cancer
and HRT and reported that HRT decreases cardiovascular
events [87].
4. Issues Favoring One
Hypothesis over the Other
4.1. Causality. A major point in the debate about the real
impact of vitamin D deficiency on extraskeletal complica-
tions is whether 25(OH)D belongs to the causal pathway. In
other words, does a low 25(OH)D level cause disease or is
it simply a side effect of either the exposure (e.g., sedentary
behavior or obesity) or disease (e.g., cancer or autoimmune
disease)? While an RCT (i.e., the supreme paradigm for
epidemiological research [88]) is the best study design to
determine causality, risk factors, such as low 25(OH)D levels,
cannot be assessed with this type of trial for obvious ethical
reasons. Observational studies, which are prone to spurious
results, are then conducted. This issue of study design is so
central that some epidemiologists have categorized the field
into descriptive problems (i.e., a parameter of occurrence
is related to a determinant without a causal interpretation
of the relationship) and causal problems [88]. A causal
interpretation of the relationship of an outcome parameter
(type II diabetes) to a determinant (25(OH)D) can be given
as long as the relationship is conditional on the entire set
of potential confounders (both known and unknown). This
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requisite conditionality is best pursued by randomization [88]
and thus the use of RCTs.
4.2. Confounding and Reverse Causation. Confounding hap-
pens when the effect of at least one extraneous factor (e.g.,
bodymass index, BMI) ismixedwith the effect of an exposure
of interest (25(OH)D), thus distorting the estimate of the
latter [89]. With respect to vitamin D, the list of potential
known confounders is very large and includes the following
major ones. (1) Age: the production of vitamin D by the
skin decreases with age [2]. (2) BMI: the reasons for the
inverse association between BMI and 25(OH)D level are
not completely understood, but fat in the skin seems to
decrease the efficacy of vitamin D synthesis, which may
be due to 7-dehydrocholesterol sequestration. Of note, this
inverse association could also be confounded by a decrease
in sun exposure (e.g., a decrease in outdoor physical activity
or comorbidities). (3) Latitude and seasons: theoretically,
persons living in regions closer to the equator should present
with higher levels of vitamin D synthesis than those residing
in regions remote from the equator. In practice, however,
because more than 90% of vitamin D arises from sunlight (in
the absence of supplementation), levels of this vitamin also
depend on cultural behaviors (clothing, time spent outdoors,
and sunbathing habits). Overall, reports of the effect of lati-
tude on serum 25(OH)D have been inconsistent [90–92]. A
positive correlation between 25(OH)D and latitude has been
found in a (25 European countries) pooled analysis, whereas
the highest rate of 25(OH)D deficiency has been observed
in Scottish participants (highest latitude) in a British cross-
sectional study [91]. However, recent metaregression analysis
did not find an influence of latitude on 25(OH)D level
[92]. (4) Skin pigmentation: the packaging and sizes of
melanosomes in keratocytes influence the darkness of the
skin. Dark pigments in the skin reduce its ability to synthesize
vitamin D from sunlight by up to 95% [22]. This fact
likely explains why African-Americans have lower 25(OH)D
than non-Hispanic whites in the US [22]. The darker skin
pigmentation in individuals residing in southern compared
to northern European countries may underlie the higher
prevalence of 25(OH)D deficiency in southern Europe [93].
(5)Diet: diets typically contain only small amounts of vitamin
D (vitamin D
3
or vitamin D
2
). Fish is the major dietary
source of vitamin D in humans. Three ounces of cooked
salmon and 3.5 ounces of cooked mackerel provide 90%
and 86%, respectively, of the recommended daily vitamin
D intake (400–600 international units/day), whereas 3.5
ounces of cooked beef only provides 4% of the recommended
intake. (6) Occasional sunscreen: sunscreen use by children
and young adults is unlikely to cause vitamin D deficiency,
but the chronic use of sunscreen by elderly individuals has
been shown to decrease 25(OH)D and to cause vitamin D
deficiency. (7) Altitude, air pollution, ozone, time of the day,
and cloud cover: at higher altitudes,UVB radiation is stronger
because the concentrations of aerosols and particles are lower.
Air pollution decreases vitaminD-effective radiation. Ozone,
time of the day, and cloud cover also influence vitamin
D-effective radiation and thus vitamin D photosynthesis.
Other potential confounders include genetic and epigenetic
(i.e., heritable and modifiable changes in gene expression
that do not affect DNA sequences) variations that have
been implicated in association with vitamin D that may
contribute to the interindividual variability of the impacts
of its deficiency and/or supplementation [29, 94]. Disregard-
ing the unknown potential confounders, fully accounting
for all of these potential known confounders is practically
impossible (residual confounding) unless randomization is
used.
Temporality in causal criteria refers to the necessity
that the cause precedes the effect in time (causal sequence)
[89]. Thus, reverse causation refers to a situation in which
an outcome precedes and causes an exposure instead of
the other way around [95]. Autier et al. have performed
a systematic review of vitamin D status and ill health and
have concluded that the discrepancies between observa-
tional and intervention studies indicate that low 25(OH)D
is a marker, not a cause, of ill health [96]. These authors
have notably proposed that the wide range of disorders
associated with low 25(OH)D is explained by the fact
that inflammatory processes involved in disease occur-
rence and clinical course reduce 25(OH)D. Other groups
have stressed that 25(OH)D is an unreliable biomarker
of vitamin D status after an acute inflammatory insult
[97].
Although subgroup analysis of a recent meta-analysis of
observational studies has suggested that the inverse associa-
tion of 25(OH)D level with mortality is stronger in popula-
tions with low prevalences of vitamin D supplementation or
low 25(OH)D levels [76], this finding can still be attributed to
reverse causation, withmore severe underlying diseases being
associated with lower 25(OH)D levels.
4.3. Mendelian Randomization. Randomization in observa-
tional studies is not possible, but an alternative exists, which
is termed Mendelian randomization (MR). MR is being
increasingly used to overcome confounding and reverse
causation for exploring causal effects of an exposure on
a disease in nonexperimental studies. The concept of MR
refers to the random allocation of alleles at the time of
gamete formation. By analogy with the fact that the random
allocation of a treatment in a RCT renders confounding
unlikely, a genetic variant of interest should not be associated
with known and unknown confounding factors [98, 99]. MR
studies have been conducted to infer causality for vitamin D
and extraskeletal complications, such as high blood pressure
and type II diabetes. Genetic variants that specifically alter
25(OH)D levels, which are usually identified from genome-
wide association studies (GWAS), are generally used. For
example, Kunutsor et al. have used 4 variants (in theDHCR7,
CYP2R1, GC, and CYP24A1 genes) as instrumental variables
in a small sample (unknown 𝑁), failing to show a causal
role of 25(OH)D in the etiology of high blood pressure
[100]. Vimaleswaran et al. have used the same 4 variants
but have considered allelic scores and used a large sample
(𝑁 = 146,581), reporting that each 10% increase in genetically
instrumented 25(OH)D concentration is associated with an
8% decreased odds of hypertension [101]. Using the same
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variants as mentioned above but not considering allelic
scores, Ye et al. have also estimated the unconfounded causal
associations of 25(OH)D concentration with the risks of
type II diabetes and other glycemic traits using an MR
approach [102], reporting insignificantMR-derived estimates
for type II diabetes and glycemic traits and suggesting that
the association between 25(OH)D and type 2 diabetes is not
causal.
Of note, there are commonly acknowledged necessary
conditions for MR to provide a causal inference in obser-
vational epidemiology [98, 99]. One condition is that the
genetic instruments (e.g., DHCR7 variants) affect the out-
come (e.g., extraskeletal complication) by no other means
than through the exposure (25(OH)D), which is never the
case with respect to common complex human diseases.
Additionally, one cannot exclude that a true causal variant
may be in linkage disequilibrium with the genetic instru-
ments (genetic variants) used. Results obtained using theMR
approach should therefore be interpreted cautiously.
4.4. Measurement Error and Misclassification
4.4.1. Is 25(OH)D a Good Biomarker of Vitamin D Intake
and/or Function? 1,25(OH)2D is the active form of vitamin
D, but because 25(OH)D has a much longer circulating half-
life, circulates at higher concentrations, and is less influenced
by other hormones, such as PTH, it is used to determine
vitamin D status. Because of its long half-life in circulation,
25(OH)D reflects vitaminD supply and usage over a period of
time. Circulating 25(OH)D is also a better marker of vitamin
D exposure than indirect estimates of vitamin D exposure
based solely on diet, which do not take into consideration
sunlight sources [103].
However, as discussed elsewhere [104], serum 25(OH)D
concentration is influenced by several factors, such as the
quantity of vitamin D delivered to the liver, the amount of
25(OH)D produced by the liver, and the half-life of 25(OH)D
in the serum. These factors are themselves influenced by
several determinants (sunlight exposure, intestinal absorp-
tion, body fat, 25-hydroxylase activity, VDBP production
in the liver, etc.) [104]. Prentice et al. have stressed that
because serum 25(OH)D has little interaction with VDRs,
it might be a good biomarker of intake but not of func-
tion [104]. Therefore, other biomarkers of vitamin D func-
tion have been proposed (e.g., the 1,25(OH)2D/25(OH)D
ratio, 1,25(OH)2D/24,25(OH)2D ratio, and >35 additional
25(OH)D metabolites formed by the body). However, evalu-
ating such biomarkers in large epidemiological studies is diffi-
cult. Additionally, serial measurements in the same individu-
als are ideal but rarely feasible. Therefore, it is not excluded
that 25(OH)D, when used as a biomarker of extraskeletal
complications, provides biased associations similar to many
other biomarkers, as demonstrated in a recent systematic
evaluation of 56 meta-analyses of emerging cardiovascu-
lar biomarkers (e.g., C-reactive protein and homocysteine)
[105].
Even if we agree that 25(OH)D is sufficiently linked to
active 1,25(OH)D and is the best marker of vitamin D status
similar to the conclusion of a meta-analysis performed by
Tzoulaki et al. [105], it is worth noting that results vary
markedly depending on the assay used [106, 107]. Liquid
chromatography tandem mass spectrometry (LC-MS/MS)
remains the gold standard technique to measure 25(OH)D
[106, 108].
4.5. Deficiency versus Supplementation and Life-Course Per-
spective. Different factors that could explain the lack of
replication in the few RCTs of the results reported by several
observational studies have been discussed. For example, it
has been suggested that the impact of vitamin D deficiency
(as determined in observational studies) is not the same as
the effect of vitamin D supplementation (as determined in
RCTs), particularly in participants with sufficient vitamin D
levels [109].Other groups have suggested that the relationship
of 25(OH)D with the risk of extraskeletal complications
could be observable only at low levels of 25(OH)D [26, 109].
Davis has also suggested that the risk associated with low
vitamin D status might be conferred earlier in life and that
studies of circulating 25(OH)D in adults do not address
the most relevant time period of exposure [26]. Vitamin D
may play pivotal roles throughout life not only in calcium
homeostasis and skeletal metabolism but also in infection
and autoimmune disease development and progression [104].
Reviews have been published on vitamin D and functional
outcomes, specifically in infants and young children [110],
adolescents [111], and elderly individuals [112].
5. Why Results from Ongoing Randomized
Controlled Trials Will Be Unlikely to
Reconcile the Two Schools of Thought
Five RCTs (the CAPS, VITAL, Do-Health, FIND, and ViDa
trials; see [20] for further details) are currently underway in
9 countries (Figure 3) to determine the impacts of vitamin
D supplementation on extraskeletal complications. Most are
well funded and sufficiently powered to detect a significant
impact, if any exist. More than 42,000 participants will be
included with a potential of 208,116 person-years, and $22
million has been invested just for the VITAL trial [113].
However, several experts have already pointed out fatal
limitations that might invalidate the (negative or null) results
of these trials [69, 114–117]. These limitations include the
following: (i) the supplementation doses of vitamin D are too
low, and higher doses should be tested; (ii) the contrast in
25(OH)D intake between the two arms is insufficient given
that control groups are producing 25(OH)D even in the
absence of the intervention; (iii) the 5-year follow up (which
some experts have attributed to be basedmore on the funding
grant cycle than on the vitamin D cycle) is too short; (iv)
the optimal vitamin D concentration may not be the same
for all extraskeletal complications considered; (v) participants
are included regardless of their 25(OH)D level at baseline,
andmost participants already have an optimal 25(OH)D level
prior to the start of the intervention.The effects of vitamin D
likely depend on the baseline vitaminD status; and (vi) future
trials are not likely to change pooled (null) estimates already
reported by meta-analyses.
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Figure 3: Countries where large randomized controlled trials are currently ongoing to determine the impact of vitaminD supplementation on
extraskeletal complications. CAPS, USA; VITAL, USA; Do-Health, Austria, Germany, Finland, France, Portugal, Switzerland; FIND, Finland;
ViDa; New Zealand. See [20] for further details.
We would like to add to these limitations the potential
risk of “medical reversal,” which is a phenomenon described
by Prasad et al. involving the identification of faults with trials
and the unwillingness to consider that an intervention might
be ineffective [118]. We believe that medical reversal is even
more likely to happen if ongoing trials report null effects
(rather than negative effects, as in the WHI trial).
6. Summary and Concluding Remarks
This debate is mostly fueled by the classical divergence
between observational and experimental results [119]. Obser-
vational studies are prone to reverse causation and confound-
ing. Associations between vitamin D status and extraskeletal
complications in observational studies could merely indicate
that vitamin D is a “simple” indicator of health status and that
compared with healthier subjects sicker subjects could have
a lower vitamin D level or status. The diversity of biological
systems with which vitamin D deficiency has been associated
(cardiovascular, diabetes, depression, neurodegenerative dis-
eases, cancer, etc.) could further suggest that this vitamin is
a marker of health status rather than a predictor of health
outcomes. However, both the wide distribution of VDRs in
humans and the influence of vitamin D on more than 3% of
the human genome could explain its broad effects on health.
RCTs assessing the efficacy of vitaminD supplementation
in reducing extraskeletal complications are ongoing. Trials
are still recruiting participants, and the first results will not
be available before the year 2017. The impacts of the ongoing
RCTs on clinical practice are of course difficult to predict,
but at least three scenarios exist as follows: favorable and
meaningful results are reported by the RCTs (scenario A);
no favorable or meaningful results are reported (scenario
B); or unfavorable results are reported (scenario C). All of
these scenarios may or may not be followed by appropriate
changes in clinical practice. Depending on the scenario, the
baseline common practice, and the capacity of change in
the common practice, the use of vitamin D as a biomarker
could be a success or failure, as proposed by Ioannidis [120].
If it is not a success, vitamin D could eventually become a
biomarker of the following: (i) “type B failure” occurs “when
a biomarker shows great promise in one ormore early studies,
but the claims are later found to be wrong or exaggerated, and
the biomarker is eventually never implemented into clinical
practice” (scenario A in a practice, in which vitaminD dosing
is not already common); (ii) “type D failure” occurs “when
a biomarker shows no or little promise, but nevertheless is
enthusiastically promoted for widespread clinical or popula-
tion use” (scenario C in a practice, in which vitaminD dosing
is already common); and (iii) “type A failure” occurs “when
a widely used biomarker that has already been implemented
in clinical practice is shown to be largely useless—or even
harmful—and therefore needs to be abandoned” (scenario C
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in a practice, in which vitamin D dosing is already common
but the common practice can be changed).
Determining 25(OH)D dosages in the absence of robust
evidence seems to already be a common practice in the
US, where sales of vitamin D supplements have increased
from $50 million in 2005 to $600 million in 2011 [121]
and where commentators already advocate clinicians to stop
costly measurements of 25(OH)D in asymptomatic patients
outside skeletal-related conditions [83, 122, 123].
Finally, while our review focused on extraskeletal com-
plications and discussed the related challenges, this debate
might not remain limited to extraskeletal complications for
long but may soon include skeletal complications. Indeed,
recent evidence has suggested that vitamin Dmight not be as
essential as previously thought for maintaining bone health
and preventing falls [64–66, 124].
Vitamin D (the solar vitamin) is likely to remain a
burning topic in coming years.
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